Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells.
DR5
TRAIL
apoptosis
conditioned medium
extracellular vesicles
receptor–ligand trafficking
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
01
2020
accepted:
09
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is considered to be a promising antitumor drug because of its selective proapoptotic properties on tumor cells. However, the clinical application of TRAIL is until now limited because of the resistance of several cancer cells, which can occur at various levels in the TRAIL signaling pathway. The role of decoy receptors that can side-track TRAIL, thereby preventing the formation of an activated death receptor, has been extensively studied. In this study, we have focused on extracellular vesicles (EVs) that are known to play a role in cell-to-cell communication and that can be released by donor cells into the medium transferring their components to recipient cells. TRAIL-induced apoptotic signaling is triggered upon the binding of two death receptors, DR4 and DR5. Here, we found that DR5 but not DR4 is present in the conditioned medium (CM)-derived from various cancer cells. Moreover, we observed that DR5 was exposed on EVs and can act as "decoy receptor" for binding to TRAIL. This results in a strongly reduced number of apoptotic cells upon treatment with DR5-specific TRAIL variant DHER in CM. This reduction happened with EVs containing either the long or short isoform of DR5. Taken together, we demonstrated that colon rectal tumor cells can secrete DR5-coated EVs, and this can cause TRAIL resistance. This is to our knowledge a novel finding and provides new insights into understanding TRAIL sensitivity.
Identifiants
pubmed: 32509779
doi: 10.3389/fcell.2020.00318
pmc: PMC7248226
doi:
Types de publication
Journal Article
Langues
eng
Pagination
318Informations de copyright
Copyright © 2020 Setroikromo, Zhang, Reis, Mistry and Quax.
Références
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19002-7
pubmed: 20956325
J Biol Chem. 2013 Mar 1;288(9):6617-28
pubmed: 23300075
Cancer Treat Rev. 2009 May;35(3):280-8
pubmed: 19117685
Trends Cell Biol. 2009 Feb;19(2):43-51
pubmed: 19144520
Cell Death Dis. 2010 Oct 21;1:e83
pubmed: 21368856
Crit Rev Oncol Hematol. 2019 Nov;143:81-94
pubmed: 31561055
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):504-509
pubmed: 28049841
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Clin Cancer Res. 2016 Jul 15;22(14):3499-512
pubmed: 26944067
Cell. 1997 Feb 7;88(3):355-65
pubmed: 9039262
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9
pubmed: 16731632
Oncotarget. 2013 Sep;4(9):1349-64
pubmed: 23988408
J Biol Chem. 1987 Jul 5;262(19):9412-20
pubmed: 3597417
Protoplasma. 2020 Jan;257(1):3-12
pubmed: 31468195
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10283-10288
pubmed: 16801533
J Biol Chem. 2011 Dec 16;286(50):43383-93
pubmed: 22020938
Development. 2016 Jul 15;143(14):2482-93
pubmed: 27436038
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Sci Rep. 2015 Nov 30;5:17319
pubmed: 26616523
J Cell Sci. 2000 Oct;113 Pt 19:3365-74
pubmed: 10984428
J Biol Chem. 2007 Apr 27;282(17):12831-41
pubmed: 17327223